Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization
- 254 Downloads
Domperidone (DOP) is extensively applied orally in the management of nausea and vomiting. Upon oral administration, its bioavailability is very poor due to its poor solubility in alkaline media. Therefore, the aim of this work was to investigate DOP-loaded solid lipid nanoparticles (DOP-SLNs) in order to sustain its release pattern and to enhance oral bioavailability. DOP-SLNs were prepared using four different lipids. Prepared DOP-SLNs were characterized for “polydispersity index (PDI), particle size, zeta potential, % entrapment efficiency (% EE), and drug release behavior.” Differential scanning calorimetry (DSC) study was carried out to illustrate the physical form of DOP and excipients. The morphology of DOP-SLNs was confirmed by scanning electron microscopy (SEM). Pharmacokinetic study on optimized DOP-SLN in comparison to tablet was performed in rats. The “particle size, PDI, zeta potential, and % EE” of optimized formulation (F5) were recorded as 201.4 nm, 0.071, − 6.2 mV, and 66.3%, respectively. DSC thermograms suggested amorphous state of DOP in various SLNs. Surface morphology of SLNs using SEM suggested spherical shape of the nanoparticles within nanometer size range. In vitro release studies confirmed that all SLN formulations possessed a sustained release over a period of 12 h (51.3% from optimized formulation) in comparison with immediate release from conventional tablets (100% after 90 min). Pharmacokinetic study showed significant enhancement in oral absorption of DOP from optimized SLN in comparison with DOP tablet. The enhancement in relative bioavailability of DOP from optimized SLN was 2.62-fold in comparison with DOP tablet.
KEY WORDSbioavailability dissolution domperidone pharmacokinetics solid lipid nanoparticles
“The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding the work through research group project No. RGP-139.”
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 6.Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998;20:438–53.CrossRefPubMedGoogle Scholar
- 12.Prajapati S, Patel L, Patel C. Floating matrix tablets of domperidone formulation and optimization using simplex lattice design. Iranian J Pharm Res. 2011;10:447–55.Google Scholar
- 18.Patel R, Shah D. Nanoparticles loaded sublingual film as an effective treatment of chemotherapy induced nausea and vomiting. Int J Pharm Technol Res. 2015;8:77–87.Google Scholar
- 24.Klimkowska MB, Zywiec K, Poteulas A, Szutowski M. Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Rep. 2007;59:752–6.Google Scholar
- 25.Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.Google Scholar
- 27.Torchilin V. Handbook of nanobiomedical research: fundamentals, applications and recent developments, vol. 1–4. World Scientific Publishing, Singapore, Hackensack (NJ), London, 2014.Google Scholar
- 34.Kotikalapudi LS, Adepu L, Ratna JV, Diwan PV. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles. Int J Pharm Biomed Res. 2012;3:22–9.Google Scholar
- 42.Heykants J, Knaeps A, Meuldermans W, Michiels M. On the pharmacokinetics of domperidone in animals and man I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats. Eur J Drug Metab Pharmacokinet. 1981;6:27–36.CrossRefPubMedGoogle Scholar